For instance, the advent of monoclonal antibodies targeting tumor necrosis factor-alpha (TNF-α) or integrins has revolutionized inflammatory bowel diseases management, offering clinical remission for patients unresponsive to conventional therapy [6]. Here, TNF is linked to inflammatory bowel disease.